138926-19-9 Usage
Description
[1-Hydroxy-3-(methylpentylamino)-propylidene]bisphosphonic acid sodium salt is a nitrogen-containing bisphosphonate compound, which is a white crystalline powder. It is characterized by its ability to inhibit bone resorption and is used in the treatment of various skeletal disorders.
Uses
Used in Pharmaceutical Industry:
[1-Hydroxy-3-(methylpentylamino)-propylidene]bisphosphonic acid sodium salt is used as a bone resorption inhibitor for the treatment of osteoporosis, metastatic disease, and Paget's disease. It works by inhibiting the activity of osteoclasts, which are cells responsible for bone resorption, thus helping to maintain bone density and strength.
Used in Medical Imaging:
[1-Hydroxy-3-(methylpentylamino)-propylidene]bisphosphonic acid sodium salt is used as an anthypercalcemic agent and is complexed with technetium Tc 99m for bone imaging. This allows for the visualization of bone structure and the detection of abnormalities, such as tumors or fractures, in patients.
Used in Research and Development:
[1-Hydroxy-3-(methylpentylamino)-propylidene]bisphosphonic acid sodium salt is also used as an inhibitor of FDPS (farnesyl diphosphate synthase) in research and development. This enzyme plays a role in the synthesis of cholesterol and other isoprenoids, and its inhibition can have potential applications in the treatment of various diseases, including cancer.
Mechanism of action
The action of ibandronate on bone tissue is based on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Ibandronate inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.
Pharmacokinetics
AbsorptionThe absorption of oral ibandronate occurs in the upper gastrointestinal tract. Plasma concentrations increase in a dose-linear manner up to 50 mg oral intake and increases nonlinearly above this dose.Following oral dosing, the time to maximum observed plasma ibandronate concentrations ranged from 0.5 to 2 hours (median 1 hour) in fasted healthy postmenopausal women. The mean oral bioavailability of 2.5 mg ibandronate was about 0.6% compared to intravenous dosing. The extent of absorption is impaired by food or beverages (other than plain water). The oral bioavailability of ibandronate is reduced by about 90% when BONIVA is administered concomitantly with a standard breakfast in comparison with bioavailability observed in fasted subjects. There is no meaningful reduction in bioavailability when ibandronate is taken at least 60 minutes before a meal. However, both bioavailability and the effect on bone mineral density (BMD) are reduced when food or beverages are taken less than 60 minutes following an ibandronate dose.DistributionAfter absorption, ibandronate either rapidly binds to bone or is excreted into urine. In humans, the apparent terminal volume of distribution is at least 90 L, and the amount of dose removed from the circulation via the bone is estimated to be 40% to 50% of the circulating dose. In vitro protein binding in human serum was 99.5% to 90.9% over an ibandronate concentration range of 2 to 10 ng/mL in one study and approximately 85.7% over a concentration range of 0.5 to 10 ng/mL in another study.MetabolismThere is no evidence that ibandronate is metabolized in humans.https://www.accessdata.fda.gov
References
1) Russell (2006), Ibandronate: Pharmacology and preclinical studies; Bone 38 S7
Check Digit Verification of cas no
The CAS Registry Mumber 138926-19-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,8,9,2 and 6 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 138926-19:
(8*1)+(7*3)+(6*8)+(5*9)+(4*2)+(3*6)+(2*1)+(1*9)=159
159 % 10 = 9
So 138926-19-9 is a valid CAS Registry Number.
InChI:InChI=1/C9H23NO7P2.Na.H2O/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17;;/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17);;1H2/q;+1;/p-1
138926-19-9Relevant articles and documents
Preparation method of sodium ibandronate
-
Paragraph 0019; 0020; 0023; 0024; 0025; 0028; 0029; 0033, (2017/07/04)
Relating to the technical field of pharmaceutical synthesis, the invention provides a preparation method of sodium ibandronate. The preparation method includes: taking 3-methylamino propanenitrile as the raw material to prepare 3-(N-methyl-N-n-amylamine)propionic acid hydrochloride, then reacting the 3-(N-methyl-N-n-amylamine)propionic acid hydrochloride with phosphorous acid and phosphorus trichloride to obtain ibandronic acid, and subjecting the ibandronic acid and sodium hydroxide to salification so as to obtain sodium ibandronate. The preparation method of sodium ibandronate provided by the invention reduces the refining frequency, lowers the refining loss, avoids the defects of low yield and long period brought about by a lot of refining steps, and the great harm to human and environment, and has the advantages of simple operation, good process repeatability and easy industrial production.
PROCESS FOR THE PREPARATION OF 3-(N-METHYL-N-PENTYL)AMINO-1-HYDROXYPROPANE-1,1-DIPHOSPHONIC ACID SALT OR DERIVATIVES THEREOF
-
Page/Page column 7-8, (2012/02/02)
The present invention relates to an improved process for the preparation of 3-(N-methyl-N- pentyl)amino-1-hydroxypropane-1,1-diphosphonic acid, monosodium salt, or its derivatives, in substantially pure crystalline form.
A PROCESS FOR THE SYNTHESIS OF 1-HYDROXY-3-(N-METHYLPENTYLAMINO) PROPYLIDENE BISPHOSPHONIC ACID MONOSODIUM SALT, MONOHYDRATE
-
Page/Page column 9-10, (2011/02/24)
A process for the synthesis of 1-hydroxy-3-(N-methylpentylamino) propylidene bisphosphonic acid monosodium salt, monohydrate which consists in the reaction of phosphorus trichloride with an aqueous solution of 3-(N-methylpentylamino)propionic acid hydrochloride at a temperature of 0-80°C, removing excess unreacted phosphorus trichloride, hydrolysis of the reaction mixture under reflux, conversion of 1-hydroxy-3-(N- methylpentylamino) propylidene bisphosphonic acid into its monosodium salt using sodium cation-containing alkaline substances, crystallisation using an anti-solvent. Also disclosed is a process for the synthesis of a polymorphic form of 1-hydroxy-3-(N-methylpentylamino) propylidene bisphosphonic acid monosodium salt, monohydrate which consists of initiating and carryout the crystallisation using acetone at a temperature of 0-5°C.